scholarly journals Anti-inflammatory Mechanism of Rhein in Treating Asthma Based on Network Pharmacology

2020 ◽  
Author(s):  
Junfang Feng ◽  
Ou Chen ◽  
Yibiao Wang

Abstract BackgroundNetwork pharmacology was used to study Rhein -target-pathway and to clarify its anti-inflammatory mechanism in the treatment of asthma.and provide a new idea for the treatment of asthmaMethodsThis method, which allows using network pharmacology to figure out the operational mechanism of Rhein-Target-Pathway, defines the effect of anti-inflammatory in treating asthma. The platform of Traditional Chinese Medicine Molecular Mechanism Bioinformatics, a web server for network, is used to get the corresponding target of Rhein and permit molecular docking. Cytoscape3.7.1, a kind of network software, is used to construct Rhein-predicted target network and analyse network topology. Search anti-inflammatory targets in the database of TTD and then construct the PPI network as well as create protein interaction networks that are combined with the Rhein-predicted target network. The anti-inflammatory targets of Rhein should be presented. The asthma genes of human being can be attained from the database of NCBI Gene Database and construct correspondence vivo response network model. Find Anti-inflammatory targets of Rhein against asthma, screen anti-inflammatory targets of Rhein related with Pathogenesis of asthma. Enrichr database is used to analyse signal pathway from anti-inflammatory targets of Rhein KEGG.ResultsAccording to the study, Rhein corresponds to 17 target proteins, four anti-inflammatory targets of Rhein related to asthma(MAPK14, EGFR, ERBB2, TNFRSF1A) are probably the most important targets where asthma is treated by Rhein.ConclusionsThese four anti-inflammatory targets of Rhein related to asthma are probably the key targets in the treatment of asthma by using Rhein. For the purpose of preventing the occurrence as well as development of asthma and delaying the progress of the disease, one or some of the four anti-inflammatory targets of Rhein related to asthma can be controlled.

2020 ◽  
Author(s):  
Junfang Feng ◽  
Ou Chen ◽  
Yibiao Wang

Abstract Background: Network pharmacological methods were used to predict the anti-inflammatory targets and related pathways of rhein in the treatment of asthma, and to elucidate its mechanism of action. In addition, we validated the anti-inflammatory effects of rhein in HBE cells. Methods: The corresponding targets of rhein were obtained from the TCMSP 2.3, and molecular docking was also performed. A network of predicted rhein targets was established and analysed with Cytoscape 3.7.1. The anti-inflammatory targets in the TTD database were searched to build a PPI network, which was merged with the ingredient-target network to screen anti-inflammatory targets associated with rhein. A network of anti-inflammatory rhein targets during the in vivo treatment of asthma was constructed to screen the anti-inflammatory targets related to asthma. KEGG enrichment analysis was performed with the Enrichr database and Cytoscape 3.7.1. The expression levels of proteins in the MAPK/NF-κB signalling pathway were assessed by western blot analysis. Results: Altogether, 17 targets were obtained. Epidermal active growth factor receptor (EGFR), E-selecting (E-SELE), macrophage migration inhibitory factor (MIF), and mitogen-activated protein kinase 14 (MAPK14) might be important anti-inflammatory targets of rhein during asthma treatment. We selected the MAPK signalling pathway to determine the anti-inflammatory effects of rhein. Conclusion: The anti-inflammatory mechanism of the treatment of asthma with rhein may be related to MAPK14, EGFR, E-SELE and MIF as well as their signalling pathways. To prevent the exacerbation of asthma, instead of targeting a single pathway or a single target, all these targets and their signalling pathways should be controlled holistically. Rhein may reduce inflammation by inhibiting the MAPK/NF-κB pathway.


2021 ◽  
Vol 2021 ◽  
pp. 1-13
Author(s):  
Dandan Jiang ◽  
Xiaoyan Wang ◽  
Lijun Tian ◽  
Yufeng Zhang

Objective. To study the pharmacological mechanisms of Siwu decoction (SWD) on primary dysmenorrhea (PDM) and verify with molecular docking. Methods. The  Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) was utilized to acquire the active compounds and their corresponding target genes. The GeneCards database was utilized in the search for target genes that were associated with PDM. The intersection genes from the active target genes of SWD and those associated with PDM represented the active target genes of SWD that act on PDM. The Gene Ontology (GO) function enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were both carried out by RGUI 3.6.1 and Cytoscape 3.6.0 software. Cytoscape was also utilized for creating a compound-target network, and a protein-protein interaction (PPI) network was created through the STRING database. Molecular docking simulations of the macromolecular protein target receptors and their corresponding compounds were performed using AutoDockTool 1.5.6 and AutoDock Vina software. Results. We identified 14 active compounds as well as 97 active target genes of SWD by using the TCMSP. We compared the 97 active target genes of SWD to the 299 target genes related to PDM, and 23 active target genes for SWD that act on PDM which correlated with 11 active compounds were detected. The compound-target network as well as the PPI network were created, in addition to selecting the most essential compounds and their targets in order to create a key compound-target network. The most essential compounds were kaempferol, beta-sitosterol, stigmasterol, and myricanone. The key targets were AKT1, PTGS2, ESR1, AHR, CASP3, and PGR. Lastly, molecular docking was used to confirm binding of the target with its corresponding compound. Conclusion. The pharmacological mechanisms of SWD that act on PDM were investigated, and the active compounds in the SWD for treating PDM were further verified.


2020 ◽  
Vol 2020 ◽  
pp. 1-13
Author(s):  
Fuda Xie ◽  
Mingxiang Xie ◽  
Yibing Yang ◽  
Miaomiao Zhang ◽  
Xiaojie Xu ◽  
...  

Reduning Injection (RDNI) is a traditional Chinese medicine formula indicated for the treatment of inflammatory diseases. However, the molecular mechanism of RDNI is unclear. The information of RDNI ingredients was collected from previous studies. Targets of them were obtained by data mining and molecular docking. The information of targets and related pathways was collected in UniProt and KEGG. Networks were constructed and analyzed by Cytoscape to identify key compounds, targets, and pathways. Data mining and molecular docking identified 11 compounds, 84 targets, and 201 pathways that are related to the anti-inflammatory activity of RDNI. Network analysis identified two key compounds (caffeic acid and ferulic acid), five key targets (Bcl-2, eNOS, PTGS2, PPARA, and MMPs), and four key pathways (estrogen signaling pathway, PI3K-AKT signaling pathway, cGMP-PKG signaling pathway, and calcium signaling pathway) which would play critical roles in the treatment of inflammatory diseases by RDNI. The cross-talks among pathways provided a deeper understanding of anti-inflammatory effect of RDNI. RDNI is capable of regulating multiple biological processes and treating inflammation at a systems level. Network pharmacology is a practical approach to explore the therapeutic mechanism of TCM for complex disease.


2020 ◽  
Vol 2020 ◽  
pp. 1-11
Author(s):  
Qiu-Yue Li ◽  
Cheng-Zhi Hou ◽  
Li-Ping Yang ◽  
Xue-Lei Chu ◽  
Yuan Wang ◽  
...  

Background. Ginseng, a traditional Chinese medicine, was used to prevent and treat many diseases such as diabetes, inflammation, and cancer. In recent years, there are some reports about the treatment of lung adenocarcinoma with ginseng monomer compounds, but there is no systematic study on the related core targets and mechanism of ginseng in the treatment of lung adenocarcinoma up to now. Therefore, this study systematically and comprehensively studied the molecular mechanism of ginseng in the treatment of lung adenocarcinoma based on network pharmacology and further proved the potential targets by A549 cell experiments for the first time. Methods. The targets of disease and drug were obtained from Gene database. Subsequently, the compound-target network was constructed, and the core potential targets were screened out by plug-in into Cytoscape. Furthermore, the core targets and mechanism of ginseng in the treatment of lung adenocarcinoma were verified by MTT test, cell scratch test, immunohistochemistry, and qRT-PCR. Results. 1791 disease targets and 144 drug targets were obtained by searching the Gene database. Meanwhile, 15 core targets were screened out: JUN, MAPK8, PTGS2, CASP3, VEGFA, MMP9, AKT1, TNF, FN1, FOS, MMP782, IL-1β, IL-2, ICAM1, and HMOX1. The results of cell experiments indicate that ginseng could treat lung adenocarcinoma by cell proliferation, migration, and apoptosis. In addition, according to the results of the 15 core targets by qRT-PCR, JUN, IL-1β, IL-2, ICAM1, HMOX1, MMP9, and MMP2 are upregulated core targets, while PTGS2 and TNF are downregulated core targets. Conclusion. This study systematically and comprehensively studied 15 core targets by network pharmacology for the first time. Subsequently, it is verified that 9 core targets for ginseng treatment of lung adenocarcinoma, namely, JUN, IL-1β, IL-2, ICAM1, HMOX1, MMP9, MMP2, PTGS2, and TNF, are closely related to the proliferation, migration, and apoptosis of lung adenocarcinoma cells. This study has reference value for the clinical application of ginseng in the treatment of lung adenocarcinoma.


2020 ◽  
Vol 1549 ◽  
pp. 032024
Author(s):  
Lijuan Lv ◽  
Xulong Huang ◽  
Xiaofen Li ◽  
Rongze Fang ◽  
Xiangpei Wang ◽  
...  

2020 ◽  
Vol 86 ◽  
pp. 106727
Author(s):  
Xiu-Fang Huang ◽  
Jia-Lin Zhang ◽  
Dan-Ping Huang ◽  
Ai-Si Huang ◽  
Hui-Ting Huang ◽  
...  

2019 ◽  
Vol 1187 (4) ◽  
pp. 042090
Author(s):  
Xulong Huang ◽  
Junjie Hao ◽  
Yuqing Liang ◽  
Yuanmin Wang ◽  
Juan Kong ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document